COVID-19 VACCINATION SCHEDULE AND DOSING
AGES 12 YEARS AND OLDER

UNVACCINATED
dose/injection volume
Moderna Bivalent:
(Do NOT dilute before use)
Dark Blue Cap (gray label)
Pfizer Bivalent:
(Do NOT dilute before use)
Gray Cap

PREVIOUSLY VACCINATED
dose/injection volume
1+ DOSES
Moderna Bivalent
50 µg/0.5 mL
OR
Pfizer Bivalent
50 µg/0.5 mL
In at least 8 weeks
1+ DOSES
Moderna or Pfizer
In at least 8 weeks
BIVALENT
Moderna
30 µg/0.3 mL
OR
Pfizer
30 µg/0.3 mL
In at least 8 weeks
BIVALENT
Moderna
50 µg/0.5 mL
OR
Pfizer
50 µg/0.5 mL
In at least 8 weeks
BIVALENT
Moderna
30 µg/0.3 mL
OR
Pfizer
30 µg/0.3 mL
In at least 8 weeks
BIVALENT
Moderna
50 µg/0.5 mL

65 YEARS AND OLDER
People ages 65 years and older have the option to receive 1 additional bivalent mRNA vaccine dose at least 4 months after the first dose of a bivalent mRNA vaccine.

ADDITIONAL DOSES
dose/injection volume
Previously Received COVID-19 Vaccines
Moderna Bivalent:
(Do NOT dilute before use)
Dark Blue Cap (gray label)
Pfizer Bivalent:
(Do NOT dilute before use)
Gray Cap

Immunocompromised Guidance
For Pfizer-BioNTech
For individuals with certain kinds of immunocompromise 5 years of age and older, a single additional age-appropriate dose of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Pfizer-BioNTech COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.

Immunocompromised Guidance
for Moderna
For individuals with certain kinds of immunocompromise 6 years of age and older, a single additional age-appropriate dose of Moderna COVID-19 Vaccine, Bivalent may be administered at least 2 months following the initial dose of a bivalent COVID-19 vaccine; additional age-appropriate doses of Moderna COVID-19 Vaccine, Bivalent may be administered at the discretion of the healthcare provider, taking into consideration the individual’s clinical circumstances.

Additional Considerations
An 8-week interval between the first and second doses of Moderna and Pfizer-BioNTech COVID-19 vaccines might be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it might reduce the small risk of myocarditis and pericarditis associated with these vaccines.

See the CDC’s Guidance for latest updates and information on who is considered moderately or severely immunocompromised.